# Mental Health in Rehabilitation: Depression, Anxiety, and Adjustment

## Introduction

Mental health conditions are highly prevalent among individuals undergoing rehabilitation and significantly impact functional recovery, participation in therapy, and long-term outcomes. Depression, anxiety, and adjustment disorders are the most frequently encountered psychiatric comorbidities in rehabilitation settings. Physiatrists must be skilled in screening, diagnosing, and initiating treatment while coordinating with psychology, psychiatry, and social work colleagues.

## Epidemiology

**Post-stroke depression**: affects 30-35% of stroke survivors; most common psychiatric complication of stroke. **Depression after SCI**: prevalence of 20-30%, with lifetime rates up to 40%. **TBI and depression**: reported in 25-50% of patients, often persisting years post-injury. **Anxiety disorders**: present in 20-30% of rehabilitation populations; frequently comorbid with depression.

**Adjustment disorder**: diagnosed in up to 25% of patients during acute rehabilitation; represents a time-limited reaction to the stressor of disability. Suicidal ideation is elevated in SCI (2-3x general population) and TBI populations; routine screening is essential.

| Condition | Prevalence of Depression | Key Contributing Factors | First-Line Pharmacotherapy |
|-----------|------------------------|------------------------|--------------------------|
| Stroke | 30-35% | Neuroanatomical disruption, functional loss | SSRIs (sertraline, citalopram) |
| Spinal cord injury | 20-30% (lifetime 40%) | Loss of independence, chronic pain, social isolation | SSRIs; SNRIs if comorbid pain |
| Traumatic brain injury | 25-50% | Neurochemical disruption, hypopituitarism | SSRIs (avoid TCAs); sertraline |
| Amputation | 20-35% | Body image, phantom pain, functional limitation | SSRIs; SNRIs if pain comorbidity |

## Pathophysiology

### Biological Factors

**Neuroanatomical disruption**: lesions affecting left prefrontal cortex (stroke), limbic system, and frontostriatal circuits increase depression risk. **Neurochemical changes**: disruption of serotonergic, noradrenergic, and dopaminergic pathways. **Neuroinflammation**: elevated cytokines (IL-1, IL-6, TNF-alpha) contribute to sickness behavior and depressive symptoms. **Neuroendocrine dysfunction**: hypothalamic-pituitary-adrenal axis dysregulation; post-traumatic hypopituitarism after TBI. **Pain**: chronic pain is both a risk factor for and consequence of depression; shared neurobiological substrates.

### Psychosocial Factors

Loss of independence, roles, and identity. Social isolation and reduced community participation. Financial stress from lost employment and medical costs. Altered family dynamics and caregiver burden. Pre-existing mental health history amplifies risk.

![Biopsychosocial model illustrating the interplay of biological, psychological, and social factors contributing to depression in rehabilitation](biopsychosocial-depression-model.png)

## Screening and Assessment

**Patient Health Questionnaire-9 (PHQ-9)**: validated, widely used depression screening tool; score of 10 or greater suggests moderate depression. **Generalized Anxiety Disorder-7 (GAD-7)**: effective screening for anxiety; score of 10 or greater suggests moderate anxiety. **Columbia Suicide Severity Rating Scale (C-SSRS)**: structured assessment for suicidal ideation and behavior. **Hospital Anxiety and Depression Scale (HADS)**: useful in medically ill populations; avoids somatic symptom overlap.

Challenges in neurological populations: apathy versus depression in TBI, emotional lability (pseudobulbar affect) versus true mood disorder, fatigue and sleep disturbance from neurological injury versus depression. Screen at admission, during rehabilitation, and at follow-up transitions.

### Differential Diagnosis

**Pseudobulbar affect**: involuntary, exaggerated emotional expression disproportionate to underlying mood; common after stroke and TBI; treated with dextromethorphan/quinidine. **Apathy**: reduced motivation and goal-directed behavior without sadness; distinct from depression; common in frontal lobe injuries. **Delirium**: fluctuating attention and cognition; must be excluded before diagnosing mood disorder in acute settings. Medication-induced mood changes: corticosteroids, beta-blockers, antiepileptics, opioids.

## Adjustment to Disability

Adjustment is **not a linear stage-based process**; the Kubler-Ross model is outdated for disability adjustment. Contemporary models emphasize **individual variability**, resilience, and meaning-making. Most individuals adapt successfully over time; persistent maladjustment may indicate clinical depression or anxiety disorder. Factors promoting positive adjustment: strong social support, internal locus of control, pre-injury coping skills, access to peer mentoring, and meaningful occupation.

The **disability paradox**: many individuals with severe disabilities report good quality of life, challenging clinician assumptions.

## Pharmacological Treatment

### Antidepressants

**SSRIs** (sertraline, citalopram, escitalopram): first-line; favorable side effect profile; evidence for post-stroke depression. **SNRIs** (venlafaxine, duloxetine): useful when comorbid neuropathic pain is present. **Bupropion**: activating; lower risk of sexual dysfunction and weight gain; use with caution in seizure-prone populations (TBI). **Mirtazapine**: useful when insomnia, poor appetite, or weight loss are prominent; sedating.

**TCAs** (nortriptyline, amitriptyline): effective but higher side effect burden (anticholinergic effects, cardiac conduction); use with caution in elderly and TBI.

### Anxiolytics

SSRIs and SNRIs are first-line for generalized anxiety and PTSD. **Buspirone**: non-sedating; useful adjunct for anxiety without dependence risk. **Benzodiazepines**: avoid in TBI and elderly; impair neuroplasticity, increase fall risk, cause cognitive impairment. **Pregabalin/gabapentin**: may address comorbid anxiety and neuropathic pain.

### Prescribing Considerations in Rehabilitation

Start low, go slow; titrate based on response and tolerability. Allow adequate trial duration (4-6 weeks at therapeutic dose) before switching. Avoid medications that lower seizure threshold in TBI patients (bupropion requires careful risk-benefit analysis). Monitor for hyponatremia (SIADH) with SSRIs, particularly in elderly and brain-injured patients. Address polypharmacy; review all medications for psychiatric side effects.

![Table comparing commonly used antidepressants in rehabilitation with key considerations for neurological populations](antidepressant-comparison-table.png)

## Psychotherapeutic Interventions

**Cognitive behavioral therapy (CBT)**: strongest evidence base; effective for depression and anxiety in SCI, stroke, and chronic pain populations; adapted versions available for cognitive impairment. **Acceptance and commitment therapy (ACT)**: promotes psychological flexibility; growing evidence in chronic pain and disability adjustment. **Motivational interviewing**: addresses ambivalence about therapy participation and health behavior change. **Mindfulness-based stress reduction (MBSR)**: reduces anxiety, pain, and perceived stress.

**Supportive psychotherapy**: validation, psychoeducation, and problem-solving; appropriate for adjustment reactions. **Group therapy and peer support**: reduces isolation; shared experience promotes coping and hope.

## Rehabilitation-Specific Considerations

Depression reduces therapy participation, motor recovery, and rehabilitation length-of-stay efficiency. Treating depression improves functional outcomes in stroke rehabilitation (evidence from multiple RCTs). Collaborative care models integrating psychology and psychiatry within the rehabilitation team yield superior outcomes. **Caregiver mental health**: screen and address caregiver depression and burden; caregiver well-being directly impacts patient outcomes.

Transition points (discharge from inpatient rehabilitation, return to community) are high-risk periods for mood deterioration. ![Collaborative care model for mental health integration in the rehabilitation team](collaborative-care-model.png)

## Key Clinical Pearls

Screen every rehabilitation patient for depression and suicidal ideation using validated tools (PHQ-9, C-SSRS) at admission and at key transitions. Distinguish pseudobulbar affect from depression: PBA involves episodes of involuntary laughing or crying disproportionate to mood and is treated with dextromethorphan/quinidine, not antidepressants alone. Avoid benzodiazepines in TBI and elderly rehabilitation populations due to impaired neuroplasticity, increased fall risk, and cognitive side effects. Treating depression is not merely supportive care; it directly improves motor recovery and functional outcomes, particularly after stroke. Adjustment to disability is highly individual; avoid imposing stage-based models and recognize that most patients demonstrate remarkable resilience over time.

## References

1. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. *International Journal of Stroke*. 2014;9(8):1017-1025.
2. Fann JR, Hart T, Schomer KG. Treatment for depression after traumatic brain injury: a systematic review. *Journal of Neurotrauma*. 2009;26(12):2383-2402.
3. Williams R, Murray A. Prevalence of depression after spinal cord injury: a meta-analysis. *Archives of Physical Medicine and Rehabilitation*. 2015;96(1):133-140.
4. Towfighi A, Ovbiagele B, El Husseini N, et al. Poststroke depression: a scientific statement for healthcare professionals from the AHA/ASA. *Stroke*. 2017;48(2):e30-e43.